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While traditionally recognized for their roles in hemostatic pathways, emerging evidence
demonstrates that platelets have previously unrecognized, dynamic roles that span the
immune continuum. These newly recognized platelet functions, including the secretion of
immune mediators, interactions with endothelial cells, monocytes, and neutrophils, toll-like
receptor (TLR) mediated responses, and induction of neutrophil extracellular trap formation,
bridge thrombotic and inflammatory pathways and contribute to host defense mechanisms
against invading pathogens. In this focused review, we highlight several of these emerging
aspects of platelet biology and their implications in clinical infectious syndromes.
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INTRODUCTION
Platelets are small anucleate cells highly specialized for hemosta-
sis and vascular wall repair. Emerging data demonstrate that in
addition to their traditional hemostatic functions, platelets are
also versatile effector cells with a repertoire of functions that
span the immune continuum. These newly recognized and well-
established platelet functions bridge thrombotic and inflamma-
tory pathways and contribute to many systemic inflammatory and
immune processes and diseases (1–3). Moreover, the inflammatory
and immune specializations of platelets are likely evolutionarily
driven adaptations that augment host defenses against invad-
ing pathogens. These newly recognized platelet activities include
the release of pleiotropic immune mediators, heterotypic interac-
tions with endothelial cells, monocytes, and neutrophils, toll-like
receptor (TLR) mediated responses, and induction of neutrophil
extracellular trap (NET) formation. Here, we provide a focused
review on several of the emerging aspects of the biology of platelets
across the inflammatory and immune continuum. For additional
information on these topics, the reader is referred to several recent
reviews (1, 3–5).
Abbreviations: CLEC-2, C-type lectin-like 2; CNS, central nervous system; DAMPs,
danger associated molecular patterns; GPVI, glycoprotein VI; HIV-1, human
immunodeficiency virus 1; IL, Interleukin; LPS, lipopolysaccharide; MCP-1, mono-
cyte chemotactic protein-1; MPs, microparticles; NET, neutrophil extracellular trap;
PF4, platelet factor 4; PMNs, polymorphonuclear leukocytes; RANTES, regulated
on activation, normal T-cell expressed and secreted; ROS, reactive oxygen species;
TLR, toll-like receptor; TNF-α, tumor necrosis factor alpha.
PLATELET SURFACE LIGANDS SENSE AND RESPOND TO
PATHOGENS
The platelet surface is replete with numerous receptors that not
only regulate hemostatic responses but also trigger proinflam-
matory and immune cascades (Figure 1). Many of these sur-
face receptors have been called “immunoreceptors” in homage
of their molecular structure and the ligands they recognize (6).
For example, platelet Fc receptors bind immunoglobulins of the
IgE, IgG, and IgA class and immune complexes, directly induc-
ing immune signaling pathways. Glycoprotein VI (GPVI), which
is only found on platelets, triggers platelet microvesicle release
and subsequent inflammatory signals through interleukin (IL)-1
(7). GPVI may also be a receptor for hepatitis C, mediating viral
transport and replication mechanisms (8). Moreover, GPVI ampli-
fies platelet activation by thrombin, thus providing a mechanism
for coordinate signaling with G-protein-coupled pathways (9). C-
type lectin-like (CLEC-2) receptors, including DC-SIGN, mediate
human immunodeficiency virus 1 (HIV-1) capture by platelets
(10) and platelet activation in dengue infection (11).
Human platelets and megakaryocytes also express mRNA
and/or protein for the TLRs 1, 2, 4–7, and 9 (2, 12–15). TLRs
bind diverse ligands from many infectious pathogens, includ-
ing bacteria, viruses, parasites, and protozoa. Thus, the discovery
that human platelets possess TLRs established direct mechanisms
by which platelets may function as pathogen “sensors” (12, 16).
Moreover, by recognizing endogenous ligands as well as micro-
bial pathogen-associated molecular pattern motifs, platelet TLRs
provide pathways by which human platelets can response to danger
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FIGURE 1 | Upon activation, platelets mediate responses central to
inflammation and hemostasis. Agonists such as thrombin, collagen,
adenosine diphosphate (ADP), thromboxane A2, and LPS bind to
agonists on human platelets, triggering classic responses of platelet
activation, aggregation, adhesion, and secretion. Platelet activation also
results in protein synthetic activities, release of thrombo-inflammatory
modulators, heterotypic binding to leukocytes, and interaction with the
endothelium.
associated molecular patterns (DAMPs), whereby mediating both
infectious and non-infectious immune syndromes (17, 18).
Among the TLRs identified on platelets at either the mRNA
and/or protein level, TLR4 has been most extensively studied to
date (2, 12). TLR4 is the receptor for lipopolysaccharide (LPS), an
endotoxin component on the outer membrane of Gram-negative
organisms that elicits strong immune responses. LPS activates
human platelets both in vitro and during in vivo settings where
healthy volunteers are given low doses of LPS, although activa-
tion patterns are variable (19–22). Although still incompletely
understood, LPS-induced platelet responses include aggregation,
degranulation, secretion, pre-mRNA splicing and protein syn-
thesis, and alterations in surface CD40L. Moreover, LPS-induced
platelet activation triggers formation of NETs by polymorphonu-
clear leukocytes (PMNs), enhancing bacterial capture, and killing
(23) (Figure 2).
Emerging data have identified new and intriguing roles for
platelet TLR7 during viral infections. TLR7, which localizes to the
endosomal compartment of the cell (24), is a sensor for nucleic
acid ligands – in particular for ssRNA. Viral pathogens such as
influenza and HIV, which continue to have significant public
health burden, activate the TLR7 receptor (24). These and other
ssRNA viruses, which signal through TLR7, are associated with
thrombocytopenia, giving rise to suppositions that platelet TLR7
mediates viral sensing and/or host defense mechanisms. In recent
and elegantly performed studies (15), activation of platelet TLR7
not only induced platelet-neutrophil aggregation and a reduction
in platelet count, but was also necessary for optimal survival in
murine models of encephalomyocarditis (EMCV) viral infection.
Engagement of platelet TLR7 under these conditions, however, did
not induce platelet aggregation (15). Thus, platelet TLR7 plays a
key role in host recognition of ssRNA viruses and suggests that
platelets may be integral mediators of innate immune responses.
Toll-like receptor9, while less well examined currently, is
intriguing given its unexpected cellular localization patterns (19,
25). TLR9 is expressed on the plasma membrane and in the
cytoplasm of quiescent human platelets and its surface expression
increases upon activation of platelets with agonists such as throm-
bin (14, 25, 26). TLR9 is a ligand for unmethylated CpG islands in
viral and bacterial DNA, suggesting a previously unrecognized sys-
tem of pathogen sensing by human platelets (Figure 2). Moreover,
TLR9 binds a carboxyalkylpyrrole protein adduct that may serve
as a DAMP, resulting in platelet activation, aggregation, and gran-
ule secretion and thrombosis (27). Thus, TLR9 represents another
functional platelet receptor linking immune, inflammatory, and
thrombotic pathways.
PLATELETS SECRETE MEDIATORS THAT AUGMENT HOST
IMMUNE MECHANISMS
Activated platelets have numerous direct and indirect mecha-
nisms for delivering signals to target cells involved in immune
and inflammatory interactions (Figure 1). These diverse mech-
anisms include platelet secretion of chemokines, cytokines, and
other mediators (4). There are more than 300 proteins secreted
by platelets, the majority of which are stored in at least one of
three types of storage organelles: alpha granules, dense granules
or bodies, or lysosomes. Recently, a fourth electron-dense tubular
system compartment, called the T-granule, was discovered and,
intriguingly, co-localizes with TLR9 (25). Many of these pro-
teins translocate to the platelet surface and are released upon
platelet activation. Other secreted proteins are located basally
on the platelet membrane and/or within other subcellular stores
(Figure 1).
Protein products released by platelets orchestrate intercellular
signaling for dynamic immune and inflammatory response (1,
2, 4). For example, quiescent human platelets possess the IL-1β
pre-mRNA but almost no mature IL-1β mRNA or IL-1β protein
(28). Upon activation with agonists often present in the infec-
tious milieu, including thrombin and LPS, platelets synthesize
pro-IL-1β protein (28, 29). Components of the inflammasome,
which regulates host defense mechanisms to pathogens (30, 31),
are present within platelets and mediate conversion of pro-IL-1β
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FIGURE 2 | Platelets interact with pathogens present in the infections
milieu, increase vascular permeability, and mediate NET formation.
(A) Binding of pathogens and agonists present in the infectious milieu leads
to platelet activation and enhanced inflammatory and immune activities.
(B) Platelet-derived microparticles carry IL-1β, which increases vascular
permeability. (C) P-selectin, which is expressed on the surface of activated
platelets, induces NET formation in a reductionist model of endothelial cell
and platelet activation. PMNs isolated from healthy adult donors were
incubated on poly-L-lysine or p-selectin coated glass coverslips and assessed
qualitatively for NET formation using live cell imaging. Extracellular,
NET-associated DNA is shown in red fluorescence (Sytox Orange) and
intracellular, nuclear DNA is shown in green fluorescence (Syto Green). NET
formation by LPS-stimulated PMNs is shown as a positive control. These
images are representative of four separate experiments performed using
PMNs isolated from four different healthy adult donors (used with kind
permission from Drs. Nathan L. Thornton and Christian C. Yost).
to the mature IL-1β cytokine (2). Mature IL-1β, the gatekeeper
of inflammation, can be released by platelets into the systemic
circulation and/or packaged within platelet-derived microparti-
cles (MPs). IL-1β within platelet MPs allows for communica-
tion with and activation of extravascular cells and induction of
endothelial permeability (7, 32). Recent evidence demonstrates
that IL-1β also acts through an autocrine loop to amplify platelet
activation responses (33). Platelet shedding of IL-1β rich MPs
also may contribute to enhanced vascular permeability in hem-
orrhagic viral infections such as dengue (34) (Figure 2). Other
proteins secreted by platelets, including platelet factor 4 (PF4),
RANTES (regulated on activation, normal T -cell expressed and
secreted), CD154, transforming growth factor beta 1 (TGF-beta
1), and CD40L are involved in key pathways for innate immune
regulation, inflammation, and adaptive immune responses (1, 19,
35–38).
CLINICAL IMPLICATIONS OF PLATELET IMMUNE ACTIVITIES
Emerging and established evidence demonstrates that platelets
participate in diverse inflammatory and immune clinical syn-
dromes. While a detailed discussion is beyond the scope of this
review, the reader is referred to several recent articles summariz-
ing these activities (1–3, 12, 19, 36, 37). In the section below, we
briefly discuss several of these clinical conditions.
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Platelets are key mediators of bacterial and viral infectious syn-
dromes. Emerging and intriguing data also highlight that fungal
pathogens such as invasive aspergillosis, also induce platelet acti-
vation in vitro and in vivo. Moreover, upon activation by fungal
serine protease and the mycotoxin gliotoxin, platelets inhibit fun-
gal growth (39). These and other data demonstrate that platelet-
fungus interactions are multifaceted and complex, involving com-
plement activation, chemotactic attraction, and activation of other
immune cells such as phagocytes (40).
Among these various infectious syndromes, sepsis, malaria, and
dengue are particularly important to highlight given their com-
monness and high risk of significant morbidity and mortality (41).
Alterations in platelet number and function are integral to each
of these, yet the mechanisms underlying these changes remain
only incompletely defined. Moreover, the extent to which platelets
augment host defense mechanisms or, contrarily, induce injurious
systemic responses is unclear.
Thrombocytopenia is common in septic syndromes with clin-
ical studies demonstrating an inverse correlation between platelet
number and adverse outcomes (12, 42, 43). The precise mecha-
nisms underlying reductions in platelet counts during infectious
syndromes are not entirely clear although interferon produc-
tion during infections may contribute to impairments in throm-
bopoiesis and resulting thrombocytopenia. The precise path-
ways by which interferon causes an antiproliferative effect are
still incompletely understood but likely involve direct effects on
megakaryocytes residing within the bone marrow niche.
While many studies have focused on alterations in “traditional”
platelet activation patterns (44, 45) (e.g., adhesion, secretion,
platelet-monocyte aggregation), emerging evidence highlights the
new biology of platelets in septic syndromes. For example, in
response to in vitro stimulation LPS, thrombin, bacteria, and
bacterial toxins, human platelets process constitutively present tis-
sue facture (TF) pre-mRNA, resulting in a mature TF transcript,
synthesis of TF protein, and generation of TF-dependent procoag-
ulant activity (22). Moreover, platelets from septic patients, but not
healthy controls, express the mature, spliced TF mRNA, demon-
strating that the septic milieu may alter the platelet transcriptome.
Preliminary analyses of next-generation RNA sequencing data
(“deep sequencing”) performed on platelets from septic patients
identified numerous transcripts that are significantly altered com-
pared to matched, healthy control subjects. Many of these altered
transcripts mediate key immune and inflammatory pathways and
augment host defenses to bacterial invaders.
Dengue, a mosquito-borne viral infection, has variable clini-
cal manifestations. Nevertheless, especially in more severe cases,
marked thrombocytopenia, hemorrhage, “capillary leak,” and
shock may occur. While the dengue flavivirus targets endothelial
cells and leukocytes, interactions of the virus with platelets and
megakaryocytes is likely a central feature of the pathophysiology
and course of infection (41). Cytokines synthesized by platelets or
in response to platelet-dependent signaling of monocytes, includ-
ing IL-1β, IL-8, tumor necrosis factor (TNF)-α, and monocyte
chemotactic protein (MCP)-1 (19), are increased in plasma from
dengue patients and correlate with the degree of thrombocy-
topenia (46). Increased IL-1β in platelets and platelet MPs was
recently reported to occur through a mechanism dependent on
mitochondrial reactive oxygen species (ROS)-triggered NLRP3
inflammasomes (34). Dengue virus also alters l-arginine trans-
port and nitric oxide generation in platelets in vitro, resulting in
impaired aggregation (47). Platelets isolated from dengue patients
have evidence of mitochondrial dysfunction with activation of
apoptosis pathways, mediated through DC-SIGN (11). These find-
ings suggest that platelet dysfunction may contribute to the throm-
bocytopenia and associated hemorrhagic complications of dengue
infection.
Platelets are also likely early responder and effector cells in
malaria infections. Human platelets inhibit the growth of some
malaria species and also kill the malarial pathogen in parasitized
red blood cells (PRBCs), experimental evidence that platelets
may serve as early host defense responses to malarial infec-
tion in the vasculature (48–50). In contrast to these protective
innate immune activities, platelets may also contribute to injuri-
ous vasculopathy in severe malaria. While the mechanisms are
still not entirely understood, murine studies demonstrate that
platelet signaling via PF4 release mediates T-cell recruitment and
monocyte activation within the central nervous system (CNS)
(51). These processes may contribute to CSN injury in severe
malaria. Recent studies of patients infected with Plasmodium
vivax malaria suggest that the thrombocytopenia that commonly
occurs in malaria may be due to platelet phagocytosis (52). Taken
together, these studies and others provide experimental and clin-
ical evidence that platelets are important immune effector cells in
malaria (53, 54).
CONCLUSIONS
While traditionally thought of as primary hemostatic cells,
platelets are emerging as dynamic effector cells that sense and
respond to invading pathogens. Ongoing studies in experimen-
tal models of infection and human studies will further elucidate
the mechanisms, pathways, and processes governing the platelet’s
broad repertoire of immune functions. These previously unrecog-
nized findings may also lead to the development of novel therapies
targeting the platelet to augment host defense mechanisms.
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